Appleton Partners Incma buys $2,777,605 stake in Illumina (ILMN)

Illumina (ILMN) : Appleton Partners Incma scooped up 545 additional shares in Illumina during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 19,344 shares of Illumina which is valued at $2,777,605.Illumina makes up approximately 0.54% of Appleton Partners Incma’s portfolio.

Illumina closed down -0.62 points or -0.45% at $138.59 with 12,92,669 shares getting traded on Wednesday. Post opening the session at $139, the shares hit an intraday low of $137.3 and an intraday high of $139.7089 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Strs Ohio sold out all of its stake in ILMN during the most recent quarter. The investment firm sold 87,838 shares of ILMN which is valued $12,612,658. Reilly Financial Advisors added ILMN to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $14,359.Independent Portfolio Consultants reduced its stake in ILMN by selling 20 shares or 5.19% in the most recent quarter. The Hedge Fund company now holds 365 shares of ILMN which is valued at $63,379. Illumina makes up approx 0.02% of Independent Portfolio Consultants’s portfolio. Integrated Investment Consultants added ILMN to its portfolio by purchasing 482 company shares during the most recent quarter which is valued at $83,694. Illumina makes up approx 0.05% of Integrated Investment Consultants’s portfolio.

On the company’s financial health, Illumina reported $0.81 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Feb 2, 2016. Analyst had a consensus of $0.82. The company had revenue of $591.55 million for the quarter, compared to analysts expectations of $586.94 million. The company’s revenue was up 15.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.

Many Wall Street Analysts have commented on Illumina. Illumina was Downgraded by BofA/Merrill to ” Neutral” on Apr 19, 2016. Illumina was Downgraded by Cantor Fitzgerald to ” Hold” on Apr 19, 2016. Shares were Downgraded by Canaccord Genuity on Feb 4, 2016 to ” Hold” and Lowered the Price Target to $ 160 from a previous price target of $205 .

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.